As a drugmaker depending heavily on sales of both branded and non-branded products, Teva has said that it is uniquely affected by how medicines are selected for the Medicare drug price negotiation | ...

Amneal Pharmaceuticals, Inc. offers strong growth prospects with undervalued stock, rising revenues, reduced debt, and key ...

The global market for acute migraine treatment is on a steady growth trajectory, with sales expected to rise from USD 2,700.7 million in 2024 to USD 4,194.1 million by 2034, reflecting a CAGR of 4.5% ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

Mark J. Alberts, MD, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee ...

Eli Lilly & Co., Pfizer Inc., and other pharmaceutical giants are backing a legal battle against the Medicare agency’s drug price negotiation plan, defending a fight against how drugs are selected for ...

Eli Lilly & Co. closed 13.93% short of its 52-week high of $972.53, which the company reached on August 22nd.

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...

Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.